Antimalarial ACT price to be lowered as part of sustainability agreement
This article was originally published in Scrip
Executive Summary
The price of a leading artemisinin-based combination therapy (ACT) to treat malaria will be lowered by 30%, thanks to a new agreement between the Clinton HIV/AIDS Initiative (CHAI),